Lymphatic and/or blood vessel invasion in gastric cancer: relationship with clinicopathological parameters, biological factors and prognostic significance

J Cancer Res Clin Oncol. 2008 Feb;134(2):153-61. doi: 10.1007/s00432-007-0264-3. Epub 2007 Jul 13.

Abstract

Background: Lymphatic and/or blood vessel tumoral invasion (LBVI) is a common histopathologic finding of gastric carcinomas, which could make it an additional cost efficient marker and help in the detection of patients at risk for recurrence.

Materials and methods: The subjects of this study were 144 patients with primary gastric adenocarcinoma, who consecutively underwent surgery. LBVI was evaluated by H&E staining and complementary with immunohistochemical staining with anti-CD34. Intratumoral levels of EGFR were analyzed with a radioligand technique, whereas c-erbB-2 and tPA were determined by ELISA methods; pS2, cathepsin D and hyaluronic acid by immunoradiometric assays; and VEGFR-1 and -2 by immunohistochemical assays. The mean follow-up period for these patients was 33.1 months.

Results: LBVI was present in 46 patients (31.9%). The presence of LBVI correlated significantly with tumor stage, lymph node involvement, surgical resectability, histological type and histological grade, being present in a higher percentage among II-IV tumor stage (P = 0.0001), poorly differentiated (P = 0.01), diffuse type (P = 0.009), R1-R2 (P = 0.002) and lymph node-positive (P = 0.005) tumors. In addition, statistical analysis demonstrated that LBVI was significantly associated with a poorer overall patients' survival in the univariate analysis (P = 0.0001) as well as in the multivariate analysis (P = 0.009). However, our results failed to show any significant relationship between LBVI and any of the intratumoral biological parameters studied.

Conclusion: LBVI provides additional useful information that could be applied to identify gastric cancer patients at risk for recurrence, who might be candidates for further adjuvant therapies.

Publication types

  • Multicenter Study

MeSH terms

  • Adenocarcinoma / metabolism
  • Adenocarcinoma / secondary*
  • Adenocarcinoma / surgery
  • Adult
  • Aged
  • Aged, 80 and over
  • Antigens, CD34 / metabolism
  • Biomarkers, Tumor / metabolism
  • Blood Vessels / pathology*
  • Enzyme-Linked Immunosorbent Assay
  • ErbB Receptors / metabolism
  • Female
  • Follow-Up Studies
  • Humans
  • Immunoenzyme Techniques
  • Lymph Nodes / pathology*
  • Lymphatic Metastasis
  • Lymphatic Vessels / metabolism
  • Lymphatic Vessels / pathology*
  • Male
  • Middle Aged
  • Neoplasm Invasiveness
  • Prognosis
  • Receptor, ErbB-2 / metabolism
  • Stomach Neoplasms / metabolism
  • Stomach Neoplasms / pathology*
  • Stomach Neoplasms / surgery
  • Survival Rate
  • Tissue Plasminogen Activator / metabolism

Substances

  • Antigens, CD34
  • Biomarkers, Tumor
  • ErbB Receptors
  • Receptor, ErbB-2
  • Tissue Plasminogen Activator